Increased plasma HDL-cholesterol and apo A-I in breast cancer patients undergoing adjuvant tamoxifen therapy

Clinical Biochemistry

Volumn 33, Issue 6, 2000, Pages 513-516

  Mastroianni, Antonio ^a   Bellati, Cristina ^a   Facchetti, Giorgio ^a   Oldani, Sara ^a   Franzini, Carlo ^b   Berrino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; TAMOXIFEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; APOLIPOPROTEIN A-I; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; MIDDLE AGED; TAMOXIFEN; TRIGLYCERIDES;

EID: 0033741231     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(00)00160-0     Document Type: Article

References (24)

1. Potential role of tamoxifen in prevention of breast cancer
2. The effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women
3. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer
4. Effects of tamoxifen cardiovascular risk factors in postmenopausal women after 5 years of treatment
5. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node - Negative breast cancer
6. Effect of tamoxifen on plasma lipids and lipoproteins in postomenopausal women with breast cancer
7. The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers
8. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node - Negative breast cancer who have estrogen - Receptor positive tumours
9. The effect of tamoxifen treatment on serum cholesterol fractions in breast cancer women
10. Effect of tamoxifen on lipids and lipid metabolising marker enzymes in experimental atherosclerosis in Wistar rats
11. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer
12. Estrogen use and all cause mortality preliminary result from the Lipid Research clinics program: Follow-up study
13. The estradiol stimulated lipoprotein receptor of rat liver: A binding site that mediates uptake of rat lipoproteins containing apoproteins B and E
14. Influence of development, estrogens, and food intake on apolipoprotein A-1, A-III, and E mRNA in rat liver and intestine
15. Tamoxifen and toremifene lower cholesterol by inhibition of Δ8-cholesterol conversion to lathisterol in women with breast cancer
16. Cholesterol, lipoprotein and coronary heart disease in women
17. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women
18. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study
19. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease on symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (RE-GRESS)
20. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
21. Prevention of coronary heart disease with pravastin in men with hypercholesterolemia
22. Tamoxifen as a potential preventive agent in healthy postmenopausal women
23. Predictive value of lipid profile for salutary coronary angiographic changes in patients on a low-fat diet and physical exercise program
24. Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group